Grain Hunting on December 2nd | Open Source Securities research reports pointed out that humanwell healthcare (600079.SH) three products were first included in medical insurance, expected to contribute new performance quantities, maintaining a "buy" rating. In November 2024, Yichang humanwell injected Propofol sodium, Hydrocodone hydrochloride sustained-release tablets, and Chloramphenicol tablets were first included in the medical insurance catalog. The inclusion of these three products in medical insurance will continue to increase the market accessibility and sales potential of pharmaceuticals, further diversifying the company's profit growth points. Through continuous innovation and high-quality production, the company is expected to continue to expand its market share and enhance its competitive position in the pharmaceutical industry. The inclusion of the company's products in medical insurance this time once again increases the company's profit growth points, and anesthesia products are expected to quickly increase production. With the steady progress of shareholders' restructuring, the leading anesthetic is expected to usher in a valuation repair.
- Headlines
- Research reports spotlight | Open Source Securities: Three products of humanwell healthcare included in medical insurance for the first time, maintaining a "buy" rating
研报掘金丨开源证券:人福医药三个产品首次纳入医保,维持“买入”评级
Research reports spotlight | Open Source Securities: Three products of humanwell healthcare included in medical insurance for the first time, maintaining a "buy" rating
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Latest
17:38
Goldman Sachs upgraded Accenture to a buy rating, with a target price of $420, representing an increase of 17%.
ACN-0.53%
17:37
Bank of Beijing: Deputy President Wang Jian retired and left office due to age.
Bank Of Beijing+1.58%
17:36
Tianyou's main board IPO has been approved by the Shanghai Stock Exchange's listing committee meeting, and the company plans to raise 3.004 billion yuan.
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.